KR20210053874A - Cosmetic preparations for acne - Google Patents
Cosmetic preparations for acne Download PDFInfo
- Publication number
- KR20210053874A KR20210053874A KR1020217000961A KR20217000961A KR20210053874A KR 20210053874 A KR20210053874 A KR 20210053874A KR 1020217000961 A KR1020217000961 A KR 1020217000961A KR 20217000961 A KR20217000961 A KR 20217000961A KR 20210053874 A KR20210053874 A KR 20210053874A
- Authority
- KR
- South Korea
- Prior art keywords
- cosmetic
- chamber
- preparation
- product
- cosmetic preparation
- Prior art date
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 103
- 238000002360 preparation method Methods 0.000 title claims abstract description 47
- 206010000496 acne Diseases 0.000 title claims abstract description 25
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 24
- 241000894006 Bacteria Species 0.000 claims abstract description 18
- 241000186427 Cutibacterium acnes Species 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 9
- 238000004806 packaging method and process Methods 0.000 claims abstract description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 20
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 229920002125 Sokalan® Polymers 0.000 claims description 7
- 235000011187 glycerol Nutrition 0.000 claims description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000004584 polyacrylic acid Substances 0.000 claims description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 6
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical group OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 5
- 239000000679 carrageenan Substances 0.000 claims description 5
- 235000010418 carrageenan Nutrition 0.000 claims description 5
- 229920001525 carrageenan Polymers 0.000 claims description 5
- 229940113118 carrageenan Drugs 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 229940061570 polyglyceryl-10 stearate Drugs 0.000 claims description 4
- 239000004342 Benzoyl peroxide Substances 0.000 claims description 3
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims description 3
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 3
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 235000019400 benzoyl peroxide Nutrition 0.000 claims description 3
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 235000010446 mineral oil Nutrition 0.000 claims description 3
- 239000002480 mineral oil Substances 0.000 claims description 3
- 229940101267 panthenol Drugs 0.000 claims description 3
- 235000020957 pantothenol Nutrition 0.000 claims description 3
- 239000011619 pantothenol Substances 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229960004889 salicylic acid Drugs 0.000 claims description 3
- 229920002545 silicone oil Polymers 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 2
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 claims description 2
- NKEQOUMMGPBKMM-UHFFFAOYSA-N 2-hydroxy-2-[2-(2-hydroxy-3-octadecanoyloxypropoxy)-2-oxoethyl]butanedioic acid Chemical group CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CC(O)(C(O)=O)CC(O)=O NKEQOUMMGPBKMM-UHFFFAOYSA-N 0.000 claims description 2
- 229940100555 2-methyl-4-isothiazolin-3-one Drugs 0.000 claims description 2
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 claims description 2
- 229940099451 3-iodo-2-propynylbutylcarbamate Drugs 0.000 claims description 2
- WYVVKGNFXHOCQV-UHFFFAOYSA-N 3-iodoprop-2-yn-1-yl butylcarbamate Chemical compound CCCCNC(=O)OCC#CI WYVVKGNFXHOCQV-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 claims description 2
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 claims description 2
- 229940081733 cetearyl alcohol Drugs 0.000 claims description 2
- DHNRXBZYEKSXIM-UHFFFAOYSA-N chloromethylisothiazolinone Chemical compound CN1SC(Cl)=CC1=O DHNRXBZYEKSXIM-UHFFFAOYSA-N 0.000 claims description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 claims description 2
- WSDISUOETYTPRL-UHFFFAOYSA-N dmdm hydantoin Chemical compound CC1(C)N(CO)C(=O)N(CO)C1=O WSDISUOETYTPRL-UHFFFAOYSA-N 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 229960005150 glycerol Drugs 0.000 claims description 2
- 229940075529 glyceryl stearate Drugs 0.000 claims description 2
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 claims description 2
- 239000007764 o/w emulsion Substances 0.000 claims description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- RMGVATURDVPNOZ-UHFFFAOYSA-M potassium;hexadecyl hydrogen phosphate Chemical compound [K+].CCCCCCCCCCCCCCCCOP(O)([O-])=O RMGVATURDVPNOZ-UHFFFAOYSA-M 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 229940045898 sodium stearoyl glutamate Drugs 0.000 claims description 2
- KDHFCTLPQJQDQI-BDQAORGHSA-M sodium;(4s)-4-amino-5-octadecanoyloxy-5-oxopentanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC(=O)[C@@H](N)CCC([O-])=O KDHFCTLPQJQDQI-BDQAORGHSA-M 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- YBGZDTIWKVFICR-UHFFFAOYSA-N octinoxate Chemical compound CCCCC(CC)COC(=O)C=CC1=CC=C(OC)C=C1 YBGZDTIWKVFICR-UHFFFAOYSA-N 0.000 claims 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims 1
- 241000723346 Cinnamomum camphora Species 0.000 claims 1
- 241000919200 Propionibacterium acnes 6609 Species 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 229960000846 camphor Drugs 0.000 claims 1
- 229930008380 camphor Natural products 0.000 claims 1
- 239000003205 fragrance Substances 0.000 claims 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 23
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- -1 adipic acid diester Chemical class 0.000 description 5
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 4
- 210000001732 sebaceous gland Anatomy 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 208000020154 Acnes Diseases 0.000 description 2
- ZCTQGTTXIYCGGC-UHFFFAOYSA-N Benzyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 ZCTQGTTXIYCGGC-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 239000005792 Geraniol Substances 0.000 description 2
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 2
- 235000019501 Lemon oil Nutrition 0.000 description 2
- 206010039792 Seborrhoea Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- ISAOCJYIOMOJEB-UHFFFAOYSA-N benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229940113087 geraniol Drugs 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 230000003780 keratinization Effects 0.000 description 2
- 239000010501 lemon oil Substances 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- HEOCBCNFKCOKBX-RELGSGGGSA-N (1s,2e,4r)-4,7,7-trimethyl-2-[(4-methylphenyl)methylidene]bicyclo[2.2.1]heptan-3-one Chemical compound C1=CC(C)=CC=C1\C=C/1C(=O)[C@]2(C)CC[C@H]\1C2(C)C HEOCBCNFKCOKBX-RELGSGGGSA-N 0.000 description 1
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 description 1
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- 239000001244 (E)-1-(2,6,6-trimethyl-1-cyclohex-2-enyl)pent-1-en-3-one Substances 0.000 description 1
- AFDXODALSZRGIH-QPJJXVBHSA-N (E)-3-(4-methoxyphenyl)prop-2-enoic acid Chemical compound COC1=CC=C(\C=C\C(O)=O)C=C1 AFDXODALSZRGIH-QPJJXVBHSA-N 0.000 description 1
- QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- VPKMGDRERYMTJX-XEHSLEBBSA-N (e)-1-[(1r)-2,6,6-trimethylcyclohex-2-en-1-yl]pent-1-en-3-one Chemical compound CCC(=O)\C=C\[C@H]1C(C)=CCCC1(C)C VPKMGDRERYMTJX-XEHSLEBBSA-N 0.000 description 1
- YNANGXWUZWWFKX-UHFFFAOYSA-N 1,2-bis(4-methoxyphenyl)ethane-1,2-dione Chemical compound C1=CC(OC)=CC=C1C(=O)C(=O)C1=CC=C(OC)C=C1 YNANGXWUZWWFKX-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OLUJUQKZMDLFII-UHFFFAOYSA-N 1-phenyloct-1-en-3-ol Chemical compound CCCCCC(O)C=CC1=CC=CC=C1 OLUJUQKZMDLFII-UHFFFAOYSA-N 0.000 description 1
- DNRJTBAOUJJKDY-UHFFFAOYSA-N 2-Acetyl-3,5,5,6,8,8-hexamethyl-5,6,7,8- tetrahydronaphthalene Chemical compound CC(=O)C1=C(C)C=C2C(C)(C)C(C)CC(C)(C)C2=C1 DNRJTBAOUJJKDY-UHFFFAOYSA-N 0.000 description 1
- HMKKIXGYKWDQSV-SDNWHVSQSA-N 2-Pentyl-3-phenyl-2-propenal Chemical compound CCCCC\C(C=O)=C/C1=CC=CC=C1 HMKKIXGYKWDQSV-SDNWHVSQSA-N 0.000 description 1
- DCEUMOZSMAUPSP-UHFFFAOYSA-N 3,7-dimethyloct-6-enyl 3-methylbut-2-enoate Chemical compound CC(C)=CCCC(C)CCOC(=O)C=C(C)C DCEUMOZSMAUPSP-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- JRJBVWJSTHECJK-PKNBQFBNSA-N 3-Methyl-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one Chemical compound CC(=O)C(\C)=C\C1C(C)=CCCC1(C)C JRJBVWJSTHECJK-PKNBQFBNSA-N 0.000 description 1
- OXYRENDGHPGWKV-UHFFFAOYSA-N 3-methyl-5-phenylpentan-1-ol Chemical compound OCCC(C)CCC1=CC=CC=C1 OXYRENDGHPGWKV-UHFFFAOYSA-N 0.000 description 1
- YVSNOTITPICPTB-UHFFFAOYSA-N 4-methyl-2-(2-methylpropyl)oxan-4-ol Chemical compound CC(C)CC1CC(C)(O)CCO1 YVSNOTITPICPTB-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- OOCCDEMITAIZTP-QPJJXVBHSA-N Cinnamyl alcohol Natural products OC\C=C\C1=CC=CC=C1 OOCCDEMITAIZTP-QPJJXVBHSA-N 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 244000183685 Citrus aurantium Species 0.000 description 1
- 235000005976 Citrus sinensis Nutrition 0.000 description 1
- 240000002319 Citrus sinensis Species 0.000 description 1
- YEVACTAGDANHRH-UHFFFAOYSA-N Coniferan Chemical compound CCC(C)(C)C1CCCCC1OC(C)=O YEVACTAGDANHRH-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 1
- 240000002943 Elettaria cardamomum Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- XRHCAGNSDHCHFJ-UHFFFAOYSA-N Ethylene brassylate Chemical compound O=C1CCCCCCCCCCCC(=O)OCCO1 XRHCAGNSDHCHFJ-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 241000004871 Evernia Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 244000028419 Styrax benzoin Species 0.000 description 1
- 235000000126 Styrax benzoin Nutrition 0.000 description 1
- 235000008411 Sumatra benzointree Nutrition 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- SLHPMAOXNSLXEH-ZGVCCVRISA-N [(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl] 5-oxopyrrolidine-2-carboxylate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)C1NC(=O)CC1 SLHPMAOXNSLXEH-ZGVCCVRISA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- OOCCDEMITAIZTP-UHFFFAOYSA-N allylic benzylic alcohol Natural products OCC=CC1=CC=CC=C1 OOCCDEMITAIZTP-UHFFFAOYSA-N 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 235000014104 aloe vera supplement Nutrition 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- GUUHFMWKWLOQMM-NTCAYCPXSA-N alpha-hexylcinnamaldehyde Chemical compound CCCCCC\C(C=O)=C/C1=CC=CC=C1 GUUHFMWKWLOQMM-NTCAYCPXSA-N 0.000 description 1
- WUOACPNHFRMFPN-UHFFFAOYSA-N alpha-terpineol Chemical compound CC1=CCC(C(C)(C)O)CC1 WUOACPNHFRMFPN-UHFFFAOYSA-N 0.000 description 1
- UBNYRXMKIIGMKK-RMKNXTFCSA-N amiloxate Chemical compound COC1=CC=C(\C=C\C(=O)OCCC(C)C)C=C1 UBNYRXMKIIGMKK-RMKNXTFCSA-N 0.000 description 1
- 229940062909 amyl salicylate Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 229960002130 benzoin Drugs 0.000 description 1
- 239000001518 benzyl (E)-3-phenylprop-2-enoate Substances 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- NGHOLYJTSCBCGC-QXMHVHEDSA-N benzyl cinnamate Chemical compound C=1C=CC=CC=1\C=C/C(=O)OCC1=CC=CC=C1 NGHOLYJTSCBCGC-QXMHVHEDSA-N 0.000 description 1
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 235000005300 cardamomo Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- SVURIXNDRWRAFU-OGMFBOKVSA-N cedrol Chemical compound C1[C@]23[C@H](C)CC[C@H]3C(C)(C)[C@@H]1[C@@](O)(C)CC2 SVURIXNDRWRAFU-OGMFBOKVSA-N 0.000 description 1
- 229940026455 cedrol Drugs 0.000 description 1
- PCROEXHGMUJCDB-UHFFFAOYSA-N cedrol Natural products CC1CCC2C(C)(C)C3CC(C)(O)CC12C3 PCROEXHGMUJCDB-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- NGHOLYJTSCBCGC-UHFFFAOYSA-N cis-cinnamic acid benzyl ester Natural products C=1C=CC=CC=1C=CC(=O)OCC1=CC=CC=C1 NGHOLYJTSCBCGC-UHFFFAOYSA-N 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 235000000484 citronellol Nutrition 0.000 description 1
- 239000001926 citrus aurantium l. subsp. bergamia wright et arn. oil Substances 0.000 description 1
- 239000001071 citrus reticulata blanco var. mandarin Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- SQIFACVGCPWBQZ-UHFFFAOYSA-N delta-terpineol Natural products CC(C)(O)C1CCC(=C)CC1 SQIFACVGCPWBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- NYNCZOLNVTXTTP-UHFFFAOYSA-N ethyl 2-(1,3-dioxoisoindol-2-yl)acetate Chemical compound C1=CC=C2C(=O)N(CC(=O)OCC)C(=O)C2=C1 NYNCZOLNVTXTTP-UHFFFAOYSA-N 0.000 description 1
- 229940093468 ethylene brassylate Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 229940079204 evernia prunastri extract Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 229940043259 farnesol Drugs 0.000 description 1
- 229930002886 farnesol Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 235000019382 gum benzoic Nutrition 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N hexanedioic acid Natural products OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- WPFVBOQKRVRMJB-UHFFFAOYSA-N hydroxycitronellal Chemical compound O=CCC(C)CCCC(C)(C)O WPFVBOQKRVRMJB-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- SVURIXNDRWRAFU-UHFFFAOYSA-N juniperanol Natural products C1C23C(C)CCC3C(C)(C)C1C(O)(C)CC2 SVURIXNDRWRAFU-UHFFFAOYSA-N 0.000 description 1
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- JPTOCTSNXXKSSN-UHFFFAOYSA-N methylheptenone Chemical compound CCCC=CC(=O)CC JPTOCTSNXXKSSN-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000001627 myristica fragrans houtt. fruit oil Substances 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- AFDXODALSZRGIH-UHFFFAOYSA-N p-coumaric acid methyl ether Natural products COC1=CC=C(C=CC(O)=O)C=C1 AFDXODALSZRGIH-UHFFFAOYSA-N 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000010668 rosemary oil Substances 0.000 description 1
- 229940058206 rosemary oil Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 229940116411 terpineol Drugs 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 125000005457 triglyceride group Chemical group 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/062—Oil-in-water emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/362—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/732—Starch; Amylose; Amylopectin; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/30—Characterized by the absence of a particular group of ingredients
- A61K2800/34—Free of silicones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/84—Products or compounds obtained by lyophilisation, freeze-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/87—Application Devices; Containers; Packaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/88—Two- or multipart kits
- A61K2800/882—Mixing prior to application
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
본 발명은 2개의 공간적으로 분리된 챔버를 갖는 포장으로 구성된 화장품으로서, 제1 챔버는 균주 C. 액크네스 6609 (H1), C1, C3, D1, A5, H1, H2, H3, K1, K2, K4, K6, K8, K9, L1 및/또는 F4의 박테리아의 동결 건조물을 함유하며, 제2 챔버는 수분-함유 화장용 제조물을 함유하는, 화장품에 관한 것이다. 본 발명은 또한 이러한 제조물로 여드름을 치료하기 위한 방법에 관한 것이다.The present invention is a cosmetic consisting of a packaging having two spatially separated chambers, the first chamber is strain C. Acnes 6609 (H1), C1, C3, D1, A5, H1, H2, H3, K1, K2, It relates to a cosmetic product containing a freeze-dried product of bacteria of K4, K6, K8, K9, L1 and/or F4, the second chamber containing a moisture-containing cosmetic preparation. The invention also relates to a method for treating acne with such preparations.
Description
본 발명은 2개의 공간적으로 분리된 챔버를 갖는 포장 수단으로 구성된 화장품으로서, 제1 챔버는 균주 C. 액크네스(C. acnes) 6609 (H1), C1, C3, D1, A5, H1, H2, H3, K1, K2, K4, K6, K8, K9, L1 및/또는 F4 박테리아의 동결 건조물을 포함하며, 제2 챔버는 수분을 함유하는 화장용 제조물을 포함하는 화장품, 및 이러한 제조물로 여드름을 치료하기 위한 방법에 관한 것이다.The present invention is a cosmetic consisting of a packaging means having two spatially separated chambers, the first chamber is strain C. acnes (C. acnes) 6609 (H1), C1, C3, D1, A5, H1, H2, Cosmetics containing a freeze-dried product of H3, K1, K2, K4, K6, K8, K9, L1 and/or F4 bacteria, the second chamber containing a cosmetic product containing moisture, and treating acne with such a product It's about how to do it.
아름답고 매력적으로 보이려는 욕구는 인간 본성에 뿌리를 두고 있다. 아름다움에 대한 이상이 시간에 따라 변화되었지만, 호감가는 외형이 사람들의 자존감 및 이들의 인간에 대한 매력을 증가시키기 때문에 흠이 없는 외모를 추구하는 것은 항상 사람들의 목표가 되었다. 아름답고 매력적인 외모의 중요한 부분은 피부의 상태와 외형이다.The desire to look beautiful and attractive is rooted in human nature. Although the ideals of beauty have changed over time, pursuing a flawless appearance has always been a goal of people because likable appearances increase people's self-esteem and their attractiveness to humans. An important part of your beautiful and attractive appearance is the condition and appearance of your skin.
건강하고 정상적인 피부와 병리학적으로 변화된 여드름 피부 사이의 과도기 상태인 기름지고 불순한 피부에서, 피부는 증가된 양의 피지(지루)를 생성한다. 지루는 많은 미생물, 특히 프로피오니박테리움 액크네스(Propionibacterium acnes)(현재 쿠티박테리운 액크네스(Cutibacterium acnes), C. 액크네스로서 알려져있으며, 이는 본원에서 P. 액크네스 대신에 새로운 약어 C. 액크네스를 사용한 이유임) 및 피티로스포룸(Pityrosporum) 종의 이상적인 번식지 역할을 한다. 미생물은 피지를 글리세린 및 지방산으로 분해하며, 이는 피지선을 자극하여 이들의 생성을 증가시키고, 피부의 모낭벽을 공격하여 파괴한다. 이는 피부에 염증(뾰루지, 농포, 결절, 낭종)을 일으키며, 이는 종종 흉터를 남기면서 치유되어 불순한 피부로 고통 받는 사람의 시각적 모습에 영구적인 손상을 초래한다(W. Umbach [Hrsg.], Kosmetik, Entwicklung, Herstellung und Anwendung kosmetischer Mittel, 2nd ed. Thieme publishing house, Stuttgart, 1995).In oily and impure skin, a transitional state between healthy and normal skin and pathologically altered acne skin, the skin produces an increased amount of sebum (seborrhea). Seborrhea is known as a number of microorganisms, particularly Propionibacterium acnes (now Cutibacterium acnes , C. acnes, which is a new abbreviation C. It serves as an ideal breeding ground for species of Acnes) and Pityrosporum. Microorganisms break down sebum into glycerin and fatty acids, which stimulate the sebaceous glands to increase their production, and attack and destroy the hair follicle walls of the skin. It causes skin irritation (rashes, pustules, nodules, cysts), which heals, often leaving scars, causing permanent damage to the visual appearance of a person suffering from impure skin (W. Umbach [Hrsg.], Kosmetik. , Entwicklung, Herstellung und Anwendung kosmetischer Mittel, 2nd ed. Thieme publishing house, Stuttgart, 1995).
여드름(좁은 의미에서 심상성 여드름(Acne vulgaris))은 분비 및 각질화 장애, 후속 염증 및 가능한 흉터를 특징으로 하는 피지선 모낭의 다양한 질병을 포함한다. 심상성 여드름은 주로 사춘기에 발생하며, 일반적으로 피지선이 풍부한 피부 부위(얼굴, 목, 가슴, 등)에 집중된다. 피지선의 증식과 모낭의 각질화 장애는 심상성 여드름에 있어서 전형적인 면포 및 백화의 형성으로 인한 막힘을 초래한다(Pschyrembel, Klinisches W
여드름 피부뿐만 아니라 지성 및/또는 불순한 피부를 치료하기 위한 통상적인 제품은 일반적으로 피부를 긴장시키고 건조시키고 약간의 관리만을 제공한다는 단점을 갖는다.Conventional products for treating oily and/or impure skin, as well as acne skin, generally have the disadvantage of tense and dry the skin and provide only little care.
여드름 치료에서, 강한 산화제(예를 들어, 벤조일 퍼옥사이드)뿐만 아니라 강산성 제제(pH 4.0 미만의 pH)가 또한 사용되며, 이는 피부 산성 맨틀에 스트레스를 주고 피부를 공격하거나 부식시킨다.In the treatment of acne, strong oxidizing agents (eg, benzoyl peroxide) as well as strongly acidic agents (pH less than pH 4.0) are also used, which stress the skin's acid mantle and attack or corrode the skin.
따라서, 본 발명의 목적은 여드름(및 특히, 심상성 여드름)의 치료뿐만 아니라 지성 및 불순한 피부의 치료를 위한 관리 화장용 및/또는 피부과용 제조물로서, 종래 기술로부터 공지된 것보다 현저하게 순하며 우수한 제조물을 개발하는 것이다. 또한, 본 발명의 목적은 피부 친화적인 pH 값(pH 4.0 보다 큰 pH)에서 효과적이며, 피부를 부식시키지 않으며 기껏해야 피부의 산성 맨틀을 단지 약간만 변형시키는 여드름(및 특히 심상성 여드름)의 치료를 위한 화장용 및/또는 피부과용 제조물을 개발하는 것이다. 또한, 피부 친화적인 pH 값(pH 4.0보다 높은 pH)에서 피부에 여드름-유발 박테리아의 성장 및 확산을 억제하는 제조물을 개발해야 한다. 또한, 피부와 피지선에 있는 여드름-유발 박테리아의 농도는 이러한 제조물에 의해 현저하게 감소되어야 한다.Accordingly, it is an object of the present invention as a care cosmetic and/or dermatological preparation for the treatment of acne (and particularly acne vulgaris) as well as the treatment of oily and impure skin, which is significantly milder than that known from the prior art. It is to develop excellent products. It is also an object of the present invention to treat acne (and especially acne vulgaris), which is effective at skin-friendly pH values (pH greater than pH 4.0), does not corrode the skin and at best only slightly deforms the acidic mantle of the skin. To develop cosmetic and/or dermatological preparations for them. In addition, it is necessary to develop a product that inhibits the growth and spread of acne-causing bacteria on the skin at skin-friendly pH values (pH above pH 4.0). In addition, the concentration of acne-causing bacteria in the skin and sebaceous glands must be significantly reduced by these preparations.
이러한 과제는 놀랍게도 2개의 공간적으로 분리된 챔버를 갖는 포장 수단으로 구성된 화장품으로서, 제1 챔버는 균주 C. 액크네스 6609 (H1), C1, C3, D1, A5, H1, H2, H3, K1, K2, K4, K6, K8, K9, L1 및/또는 F4의 박테리아의 동결 건조물을 포함하며, 제2 챔버는 수분을 함유하는 화장용 제조물을 포함하는 화장품에 의해 해결된다.Surprisingly, this task is a cosmetic product consisting of a packaging means having two spatially separated chambers, the first chamber being strain C. Acnes 6609 (H1), C1, C3, D1, A5, H1, H2, H3, K1, It comprises a freeze-dried product of bacteria of K2, K4, K6, K8, K9, L1 and/or F4, the second chamber being resolved by a cosmetic product comprising a cosmetic preparation containing moisture.
동결 건조물은 제약 기술의 표준 교과서에서 취할 수 있는 박테리아의 동결 건조를 위한 통상적인 기술 방법 중 하나에 의해 (예를 들어, 덱스트란 및/또는 글리세롤의 첨가와 함께) 균주 C. 액크네스 6609 (H1), C1, C3, D1, A5, H1, H2, H3, K1, K2, K4, K6, K8, K9, L1 및/또는 F4의 박테리아로 제조될 수 있다.The lyophilisate is strain C. acnes 6609 (H1, for example, with the addition of dextran and/or glycerol) by one of the conventional technical methods for freeze drying of bacteria that can be taken in standard textbooks of pharmaceutical technology. ), C1, C3, D1, A5, H1, H2, H3, K1, K2, K4, K6, K8, K9, L1 and/or F4 bacteria.
최신 기술이 본 발명에 따른 C. 액크네스 균주를 또한 기술하고 있는 WO 2016/172196 및 WO 2018/073651을 포함하지만, 이들 개시내용은 본 발명의 방향을 가리킬 수 없는데, 왜냐하면 이는 특히 어떤 배지로 C. 액크네스 박테리아가 충분한 양으로 활성화될 수 있는지를 기재하고 있지 않기 때문이다. WO 2016/172196은 동결-건조된 박테리아를 사용할 수 있는 기본적인 가능성을 언급하고 있지만, 숙련된 사람이 이러한 박테리아를 의학적으로 무해하지만 단시간에 피부에 유효한 양으로 재활성화시키는 것은 매우 어렵다. 또한, 비전문가도 취급하기 쉬운 방식으로 감염된 피부 부위에 균일한(균질한) 농도로 박테리아를 표적 방식으로 적용할 수 있는 수단은 공개되지 않았는데, 모든 화장품이 이러한 목적에 적합한 담체인 것은 아니다. 상 분리, 응집, 제조물로부터의 침착, 점도 변화는 동결 건조물의 혼입 동안 발생하는 전형적인 문제이다. 마지막으로, 사실상 모든 화장품에는 미생물 분해로부터 보호해야하는 성분이 포함되어 있어 화장용 제조물과 박테리아의 단순한 조합의 경우 박테리아는 화장용 제조물의 보존제 성분에 의해 거의 완전히 치사당하는 것으로 추정될 수 있다.While the state of the art includes WO 2016/172196 and WO 2018/073651 which also describe the C. acnes strain according to the present invention, these disclosures cannot point to the direction of the present invention, since this is in particular C. This is because it does not state whether the Acnes bacteria can be activated in sufficient quantities. WO 2016/172196 mentions the basic possibility of using freeze-dried bacteria, but it is very difficult for a skilled person to reactivate these bacteria in an amount effective for the skin in a short time, although medically harmless. In addition, a means by which bacteria can be applied in a targeted manner in a uniform (homogeneous) concentration to the affected skin area in a manner that is easy to handle by non-professionals has not been disclosed, but not all cosmetics are suitable carriers for this purpose. Phase separation, aggregation, deposition from the preparation, and viscosity changes are typical problems encountered during incorporation of the lyophilisate. Finally, virtually all cosmetics contain ingredients that must be protected from microbial degradation, so in the case of a simple combination of a cosmetic product and bacteria, it can be assumed that the bacteria are almost completely killed by the preservative ingredients of the cosmetic product.
박테리아의 동결 건조물 이외에, 제1 챔버는 오일 및/또는 증점제와 같은 화장용 성분을 포함할 수 있다. 본 발명에 따르면 WO 2018/073651에 제안된 바와 같이 펩톤 및/또는 하이드록시에틸 셀룰로스를 첨가하는 것이 또한 유리할 수 있다.In addition to the lyophilisate of bacteria, the first chamber may contain cosmetic ingredients such as oils and/or thickeners. According to the invention it may also be advantageous to add peptone and/or hydroxyethyl cellulose as proposed in WO 2018/073651.
본 발명에 따르면, C. 액크네스 균주 C3 및/또는 K8을 사용하는 것이 바람직하다. 본 발명에 따르면 동일한 비율의 두 균주의 조합이 바람직하다.According to the present invention, it is preferred to use C. acnes strains C3 and/or K8. According to the invention, a combination of two strains of the same ratio is preferred.
본 발명에 따르면, 이들 균주(즉, C3 및/또는 K8)를 C. 액크네스 균주 A5 및/또는 F4와 조합하는 것이 특히 바람직하다.According to the invention, it is particularly preferred to combine these strains (ie C3 and/or K8) with C. acnes strains A5 and/or F4.
본 발명에 따르면, 화장용 제조물이 제2 챔버에서 4 내지 8의 pH 값을 갖는 경우 유리하다.According to the invention, it is advantageous if the cosmetic preparation has a pH value of 4 to 8 in the second chamber.
발명에 따른 생성물에 적용을 위한 적절한 일관성을 부여하기 위해, 본 발명에 따르면 화장용 제조물이 제2 챔버에 하나 이상의 증점제를 포함하는 경우 유리하다.In order to impart a suitable consistency for application to the product according to the invention, it is advantageous according to the invention if the cosmetic preparation comprises at least one thickener in the second chamber.
특히, 제2 챔버의 화장용 제조물이 적어도 500 mPas의 점도를 갖는 경우 본 발명의 목적에 유리하다. 본 발명에 따르면, 점도는 25℃의 온도에서 분당 62.5의 일정한 속도로 스핀들 측정 본체 1이 있는 Rheomat R 123 장치로 측정된다.In particular, it is advantageous for the purposes of the present invention if the cosmetic preparation in the second chamber has a viscosity of at least 500 mPas. According to the invention, the viscosity is measured with a Rheomat R 123 device with a spindle measuring body 1 at a constant speed of 62.5 per minute at a temperature of 25°C.
본 발명에 따르면, 제2 챔버의 화장용 제조물이 카라기난 및/또는 폴리아크릴산을 포함하는 경우 바람직하다. 본 발명에 따르면, 용어 폴리아크릴산은 또한 이 화합물의 염(특히 나트륨 염)을 포함한다.According to the present invention, it is preferable when the cosmetic preparation of the second chamber contains carrageenan and/or polyacrylic acid. According to the invention, the term polyacrylic acid also includes salts (especially sodium salts) of this compound.
제조물이 카라기난을 포함하는 경우, 본 발명에 따르면 제2 챔버의 화장용 제조물의 총 중량을 기준으로 하여 0.01 내지 1 중량%의 농도가 바람직하다.When the product contains carrageenan, according to the present invention, a concentration of 0.01 to 1% by weight is preferred based on the total weight of the cosmetic product in the second chamber.
제조물이 폴리아크릴산(카르보머)을 포함하는 경우, 본 발명에 따르면 제2 챔버의 화장용 제조물의 총 중량을 기준으로 하여 0.01 내지 1 중량%의 농도가 바람직하다.When the product contains polyacrylic acid (carbomer), according to the present invention, a concentration of 0.01 to 1% by weight is preferred based on the total weight of the cosmetic product in the second chamber.
한편, 본 발명에 따르면 제2 챔버의 제조물을 잔탄 검으로 증점시키는 것이 불리한데, 왜냐하면 이러한 경우 제조물에 응집 및 엉김이 발생할 수 있기 때문이다.Meanwhile, according to the present invention, it is disadvantageous to thicken the product in the second chamber with xanthan gum, because in this case, agglomeration and agglomeration may occur in the product.
따라서, 본 발명의 유리한 구현예는 제2 챔버의 화장용 제조물이 잔탄 검을 함유하지 않음을 특징으로 한다.Thus, an advantageous embodiment of the invention is characterized in that the cosmetic preparation in the second chamber does not contain xanthan gum.
본 발명에 따르면, 제2 챔버의 화장용 제조물이 파라벤, 메틸이소티아졸리논, 클로로메틸이소티아졸리논, 3-아이오도-2-프로피닐 부틸카르바메이트, DMDM 히단토인, 2-하이드록시-4-메톡시벤조페논, 4-메톡시 신남산 (2-에틸헥실)에스테르, 4-메톡시 신남산 이소아밀 에스테르, 3-(4-메틸벤질리덴) 캄포르를 함유하지 않은 경우 유리하다.According to the present invention, the cosmetic product of the second chamber is paraben, methylisothiazolinone, chloromethylisothiazolinone, 3-iodo-2-propynyl butylcarbamate, DMDM hydantoin, 2-hydroxy It is advantageous if it does not contain -4-methoxybenzophenone, 4-methoxy cinnamic acid (2-ethylhexyl) ester, 4-methoxy cinnamic acid isoamyl ester, and 3-(4-methylbenzylidene) camphor .
본 발명에 따르면, 일반적으로 제2 챔버의 화장용 제조물이 항균 활성 물질을 함유하지 않은 것이 바람직하다. 따라서, 본 발명에 따른 생성물의 제2 챔버는 유리하게는 충전이 무균 상태에서 수행되고, 그 후 챔버가 기밀 밀봉되고 그 내용물이 단일 추출(1회 사용)에 의해 추출 장치를 통해 저장 용기에서 제거되고, 제1 챔버의 동결 건조물과 혼합후 즉시 적용되는 방식으로 설계된다.According to the invention, it is generally preferred that the cosmetic preparation in the second chamber does not contain an antimicrobial active substance. Thus, the second chamber of the product according to the invention is advantageously carried out in a sterile state, after which the chamber is hermetically sealed and its contents are removed from the storage container via the extraction device by a single extraction (one use). It is designed in such a way that it is applied immediately after mixing with the freeze-dried product in the first chamber.
본 발명의 유리한 구현예는 또한, 제2 챔버의 화장용 제조물이 글리세롤, 판테놀, 유비퀴논 Q10 및/또는 히알루론산을 포함함을 특징으로 한다.An advantageous embodiment of the invention is also characterized in that the cosmetic preparation in the second chamber comprises glycerol, panthenol, ubiquinone Q10 and/or hyaluronic acid.
제조물이 글리세롤을 포함하는 경우, 본 발명에 따르면 제2 챔버의 화장용 제조물의 총 중량을 기준으로 하여 1 내지 10 중량%의 농도가 바람직하다.When the product contains glycerol, according to the present invention, a concentration of 1 to 10% by weight is preferred based on the total weight of the cosmetic product in the second chamber.
제조물이 판테놀을 포함하는 경우, 본 발명에 따르면 제2 챔버의 화장용 제조물의 총 중량을 기준으로 하여 0.01 내지 5 중량%의 농도가 바람직하다.When the product contains panthenol, according to the present invention, a concentration of 0.01 to 5% by weight is preferred based on the total weight of the cosmetic product in the second chamber.
제조물이 히알루론산을 포함하는 경우, 본 발명에 따르면 제2 챔버의 화장용 제조물의 총 중량을 기준으로 하여 0.01 내지 2 중량%의 농도가 바람직하다.When the product contains hyaluronic acid, according to the present invention, a concentration of 0.01 to 2% by weight is preferred based on the total weight of the cosmetic product in the second chamber.
제조물이 유비퀴논 Q10을 포함하는 경우, 본 발명에 따르면 제2 챔버의 화장용 제조물의 총 중량을 기준으로 하여 0.01 내지 0.05 중량%의 농도가 바람직하다.When the product contains ubiquinone Q10, according to the present invention, a concentration of 0.01 to 0.05% by weight is preferred based on the total weight of the cosmetic product in the second chamber.
본 발명에 따르면, 제2 챔버의 화장용 제조물은 추가로 바람직하게는 항염증 물질, 예를 들어 폴리도카놀, 비사볼롤, 알로에 베라 추출물, 카모마일 꽃 추출물, 글리시리자 인플라타 뿌리 추출물을 포함할 수 있다.According to the present invention, the cosmetic preparation of the second chamber further preferably comprises an anti-inflammatory substance such as polydocanol, bisabolol, aloe vera extract, chamomile flower extract, glycyrrhiza inplata root extract. I can.
본 발명에 따르면, 제2 챔버의 화장용 제조물의 총 중량을 기준으로 하여 100 중량% 이하의 수분 함량이 제2 챔버의 화장용 제조물에 유리하다.According to the present invention, a moisture content of 100% by weight or less based on the total weight of the cosmetic product in the second chamber is advantageous for the cosmetic product in the second chamber.
본 발명에 따르면, 제2 챔버의 화장용 제조물이 살리실산, 락트산 및/또는 시트르산을 포함하는 경우 유리하다.According to the invention, it is advantageous if the cosmetic preparation of the second chamber comprises salicylic acid, lactic acid and/or citric acid.
제조물이 살리실산을 포함하는 경우, 본 발명에 따르면 제2 챔버의 화장용 제조물의 총 중량을 기준으로 하여 0.01 내지 2 중량%의 농도가 바람직하다.When the product contains salicylic acid, according to the present invention, a concentration of 0.01 to 2% by weight is preferred based on the total weight of the cosmetic product in the second chamber.
제조물이 락트산을 포함하는 경우, 본 발명에 따르면 제2 챔버의 화장용 제조물의 총 중량을 기준으로 하여 0.01 내지 3 중량%의 농도가 바람직하다.When the product contains lactic acid, according to the present invention, a concentration of 0.01 to 3% by weight is preferred based on the total weight of the cosmetic product in the second chamber.
제조물이 시트르산을 포함하는 경우, 본 발명에 따르면 제2 챔버의 화장용 제조물의 총 중량을 기준으로 하여 0.01 내지 2 중량%의 농도가 바람직하다.When the product contains citric acid, according to the present invention, a concentration of 0.01 to 2% by weight is preferred based on the total weight of the cosmetic product in the second chamber.
본 발명에 따르면, 제2 챔버의 화장용 제조물은 유리하게는 하나 이상의 향료 화합물을 포함할 수 있다. 이러한 향료 화합물은, 예를 들어 리모넨, 시트랄, 리날로올, 알파-이소메틸이오논, 게라니올, 시트로넬롤, 2-이소부틸-4-하이드록시-4-메틸테트라하이드로피란, 2-tert-펜틸사이클로헥실 아세테이트, 3-메틸-5-페닐-1-펜탄올, 7-아세틸-1,1,3,4,4,6-헥사메틸테트랄린, 아디프산 디에스테르, 알파-아밀신남알데하이드, 알파-메틸이오논, 아밀 C, 부틸페닐메틸 프로피오날신나말, 아밀살리실레이트, 아밀신나밀 알콜, 아니실 알콜, 벤조인, 벤질 알콜, 벤질 벤조에이트, 벤질 신나메이트, 벤질 살리실레이트, 베르가모트 오일, 비터 오렌지 오일, 부틸페닐 메틸 프로피오알, 카르다몬 오일, 세드롤, 신나말, 신나밀 알콜, 시트로넬릴 메틸 크로토네이트, 레몬 오일, 쿠마린, 디에틸 숙시네이트, 에틸리날올, 유제놀, 에틸렌 브라스실레이트, 에베르니아 푸르푸라세애(Evernia furfuracea) 추출물, 에베르니아 프루나스트리(Evernia prunastri) 추출물, 파르네솔, 과이액목 오일, 제라니올, 헥실 신나말, 헥실 살리실레이트, 하이드록시시트로넬랄, 라벤더 오일, 레몬 오일, 리나일 아세테이트, 만다린 오일, 멘틸 PCA, 메틸 헵테논, 육두구 오일, 로즈마리 오일, 스위트 오렌지 오일, 테르피네올, 티몰, 통카 콩 오일, 트리에틸 시트레이트 및/또는 바닐린으로 구성된 화합물의 군으로부터 선택될 수 있다.According to the invention, the cosmetic preparation of the second chamber may advantageously comprise one or more perfume compounds. Such perfume compounds are, for example, limonene, citral, linalool, alpha-isomethylionone, geraniol, citronellol, 2-isobutyl-4-hydroxy-4-methyltetrahydropyran, 2 -tert-pentylcyclohexyl acetate, 3-methyl-5-phenyl-1-pentanol, 7-acetyl-1,1,3,4,4,6-hexamethyltetraline, adipic acid diester, alpha -Amylcinnamaldehyde, alpha-methylionone, amyl C, butylphenylmethyl propionalcinnamal, amyl salicylate, amylcinnamyl alcohol, anisil alcohol, benzoin, benzyl alcohol, benzyl benzoate, benzyl cinnamate, Benzyl Salicylate, Bergamot Oil, Bitter Orange Oil, Butylphenyl Methyl Propioal, Cardamom Oil, Cedrol, Cinnamal, Cinnamyl Alcohol, Citronellyl Methyl Crotonate, Lemon Oil, Coumarin, Diethyl Succinate, Ethyllinalol, eugenol, ethylene brassylate, Evernia furfuracea extract, Evernia prunastri extract, Farnesol, fruit tree oil, geraniol, hexyl cinnamal, Hexyl Salicylate, Hydroxycitronellal, Lavender Oil, Lemon Oil, Linyl Acetate, Mandarin Oil, Menthyl PCA, Methyl Heptenone, Nutmeg Oil, Rosemary Oil, Sweet Orange Oil, Terpineol, Thymol, Tonka Bean Oil , Triethyl citrate and/or vanillin.
본 발명에 따르면, 제2 챔버의 화장용 제조물은 바람직하게는 두 가지 형태로 존재할 수 있다:According to the invention, the cosmetic preparation of the second chamber can preferably exist in two forms:
첫 번째 형태는 제2 챔버의 화장용 제조물이 수성 제조물 형태임을 특징으로 한다. 이 구현예에서, 본 발명에 따르면 제조물이 겔로서 존재하는 경우 바람직하다.The first form is characterized in that the cosmetic product in the second chamber is in the form of an aqueous product. In this embodiment, it is preferred according to the invention if the product is present as a gel.
두 번째 형태는 제2 챔버의 화장용 제조물이 수중유 에멀젼의 형태임을 특징으로 한다.The second form is characterized in that the cosmetic product in the second chamber is in the form of an oil-in-water emulsion.
이 경우, 본 발명에 따르면 제2 챔버의 화장용 제조물이 글리세릴 스테아레이트 시트레이트, 세테아릴 알콜, 소듐 세테아릴 설페이트, 글리세릴 스테아레이트, 세테아릴 설포숙시네이트, 소듐 스테아로일 글루타메이트, 폴리글리세릴-3-메틸글루코스 디스테아레이트, 스테아르산, 포타슘 세틸 포스페이트, 폴리글리세릴-10 스테아레이트(INCI 폴리글리세릴-10 스테아레이트) 및/또는 폴리클리세릴-2 카프레이트를 포함하는 경우 유리하다.In this case, according to the present invention, the cosmetic product of the second chamber is glyceryl stearate citrate, cetearyl alcohol, sodium cetearyl sulfate, glyceryl stearate, cetearyl sulfosuccinate, sodium stearoyl Glutamate, polyglyceryl-3-methylglucose distearate, stearic acid, potassium cetyl phosphate, polyglyceryl-10 stearate (INCI polyglyceryl-10 stearate) and/or polyglyceryl-2 caprate. It is advantageous if you do.
그러나, 본 발명에 따르면, W/O 에멀젼에 기초한 제조물 형태는 불리하다.However, according to the invention, the form of preparations based on W/O emulsions is disadvantageous.
본 발명의 유리한 구현예는 또한 화장용 제조물이 제2 챔버에서 전분을 포함함을 특징으로 한다.An advantageous embodiment of the invention is also characterized in that the cosmetic preparation comprises starch in the second chamber.
본 발명에 따른 화장용 제조물이 유상을 포함하는 경우(예를 들어, O/W 에멀젼이 제2 챔버에서 사용되는 경우), 본 발명에 따르면 제2 챔버의 화장용 제조물이 트리글리세리드 및/또는 옥틸도데칸올을 포함하는 경우 유리하다.When the cosmetic preparation according to the present invention contains an oil phase (for example, when an O/W emulsion is used in the second chamber), according to the present invention, the cosmetic preparation in the second chamber is triglyceride and/or octyldo. It is advantageous if it contains decanol.
또한, 유상은 레시틴, 코코글리세리드, 올리브유, 해바라기 유, 호호바 유, 대두유, 땅콩 유, 유채씨유, 아몬드 유, 팜유, 코코넛 유, 피마자유, 밀 배아 유, 포도씨 유, 홍화 오일, 달맞이꽃 오일, 마카다미아 너트 오일 등의 군으로부터의 오일을 포함할 수 있다.In addition, the oil phase is lecithin, coco glyceride, olive oil, sunflower oil, jojoba oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, castor oil, wheat germ oil, grape seed oil, safflower oil, evening primrose oil, Oils from the group such as macadamia nut oil.
반면, 제2 챔버의 화장용 제조물은 실리콘 오일, 미네랄 오일 및 폴리에틸렌 글리콜을 포함하는 경우 불리하다.On the other hand, the cosmetic product of the second chamber is disadvantageous when it contains silicone oil, mineral oil and polyethylene glycol.
따라서, 본 발명에 따르면, 본 발명의 유리한 구현예는 제2 챔버의 화장용 제조물이 실리콘 오일, 미네랄 오일 및 폴리에틸렌 글리콜을 함유하지 않음을 특징으로 한다.Thus, according to the invention, an advantageous embodiment of the invention is characterized in that the cosmetic preparation in the second chamber does not contain silicone oil, mineral oil and polyethylene glycol.
의학적으로 안전하고 미용적으로 효과적인 적용을 보장하기 위해, 동결 건조물 대 수분-함유 화장용 제조물의 균형 비가 중요하다.In order to ensure medically safe and cosmetically effective application, the balance ratio of the lyophilisate to the moisture-containing cosmetic preparation is important.
따라서, 본 발명에 따르면, 동결 건조물 대 수분-함유 화장용 제조물의 중량비가 1:10 내지 1:100인 것이 유리하다.Accordingly, according to the present invention, it is advantageous that the weight ratio of the freeze-dried product to the moisture-containing cosmetic preparation is from 1:10 to 1:100.
본 발명에 따르면, 화장품은 바람직하게는 2개 챔버의 내용물을 혼합한 후 1-10 중량%의 동결 건조물 및 99-90 중량%의 수분-함유 화장용 제조물을 포함한다.According to the present invention, the cosmetic product preferably comprises 1-10% by weight of a freeze-dried product and 99-90% by weight of a moisture-containing cosmetic preparation after mixing the contents of the two chambers.
또한, 본 발명에 따르면 동결 건조물 대 수분-함유 화장용 제조물의 비는 104 내지 107개 박테리아가 2 g 수분-함유 화장용 제조물 당 존재하게 하는 경우 유리하다.In addition, according to the invention the ratio of the lyophilisate to the moisture-containing cosmetic preparation is advantageous if 10 4 to 10 7 bacteria are present per 2 g moisture-containing cosmetic preparation.
본 발명의 유리한 구현예는 포장 수단이 두 챔버 모두의 내용물이 밀폐된 시스템에서 혼합될 수 있고, 혼합물이 개구로부터 회수될 수 있는 혼합 장치 및 회수 장치를 포함함을 특징으로 한다.An advantageous embodiment of the invention is characterized in that the packaging means comprises a mixing device and a recovery device in which the contents of both chambers can be mixed in a closed system and the mixture can be recovered from the opening.
본 발명에 따르면, 또한, 제2 챔버의 부피가 1.5 내지 2.5 cm3인 경우 유리하다.According to the invention, it is also advantageous if the volume of the second chamber is 1.5 to 2.5 cm 3.
포장 수단은 예를 들어 WO 2018/077598 A1에 개시된 것과 같은 Lyo-Ject® 이중-챔버 주사기, V-LK® 이중-챔버 카트리지 또는 이중-챔버 시스템을 포함할 수 있다.The packaging means may comprise, for example, a Lyo-Ject® double-chamber syringe, a V-LK® double-chamber cartridge or a double-chamber system as disclosed in WO 2018/077598 A1.
본 발명에 따르면 여드름의 미용 치료 방법이 또한 개시되어 있으며, 여기서 상기 기술된 본 발명에 따른 화장품의 제1 및 제2 챔버의 내용물은 혼합되고, 회수되고, 여드름의 영향을 받은 피부에 0.003 내지 0.005 g/cm2의 양으로 적용된다.According to the present invention is also disclosed a method for cosmetic treatment of acne, wherein the contents of the first and second chambers of the cosmetic according to the present invention described above are mixed, recovered, and applied to the skin affected by acne from 0.003 to 0.005. It is applied in an amount of g/cm 2.
일반적으로 두 챔버의 내용물이 함께 혼합된 후 0-12초에 피부에 적용된다.Typically, it is applied to the skin 0-12 seconds after the contents of both chambers are mixed together.
화장품을 적용하기 전에 여드름의 영향을 받은 피부를 계면활성제-함유 클렌징 제조물로 세정하는 경우 본 발명에 따른 방법에 유리하다.It is advantageous to the method according to the invention if the skin affected by acne is cleaned with a surfactant-containing cleansing preparation before applying the cosmetic product.
본 발명에 따르면, 화장품을 적용하기 전에 벤조일 퍼옥사이드를 포함하는 제조물로 여드름의 영향을 받은 피부를 소독하는 것이 또한 유리하다.According to the invention, it is also advantageous to disinfect the skin affected by acne with a preparation comprising benzoyl peroxide before applying the cosmetic product.
실시예Example
다음 실시예는 본 발명을 제한하지 않으면서 본 발명을 예시하기 위한 것이다. 모든 양, 비율 및 백분율은 달리 명시되지 않는 한 중량 및 총 수량 또는 첨가물의 총 중량과 관련이 있다.The following examples are intended to illustrate the invention without limiting the invention. All amounts, proportions and percentages relate to weight and total quantity or total weight of additives unless otherwise specified.
하기 예시적인 제형은 Lyo-Ject® 이중-챔버 주사기 또는 다중-챔버 블리스터(Rohrer AG)와 같은 포장 수단에 존재할 수 있다. 다음에서 제1 및 제2 챔버로부터의 예를 조합하였다.The following exemplary formulations may be present in packaging means such as Lyo-Ject® dual-chamber syringes or multi-chamber blisters (Rohrer AG). In the following the examples from the first and second chambers are combined.
제1 챔버[중량%]First chamber [% by weight]
보존제 없는 제2 챔버[중량%]Second chamber without preservative [% by weight]
*제1항에 언급된 C. 액크네스 균주는 표시된 양으로 개별적으로 또는 조합되어 사용된다. * The C. acnes strains mentioned in paragraph 1 are used individually or in combination in the indicated amounts.
Claims (25)
The method according to claim 23 or 24, characterized in that the skin affected by acne is disinfected with a preparation containing benzoyl peroxide prior to cosmetic application.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102018209519.1 | 2018-06-14 | ||
| DE102018209519 | 2018-06-14 | ||
| PCT/EP2019/065783 WO2019238968A1 (en) | 2018-06-14 | 2019-06-14 | Cosmetic preparation against acne |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20210053874A true KR20210053874A (en) | 2021-05-12 |
Family
ID=66998388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217000961A KR20210053874A (en) | 2018-06-14 | 2019-06-14 | Cosmetic preparations for acne |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210251885A1 (en) |
| EP (1) | EP3806820A1 (en) |
| KR (1) | KR20210053874A (en) |
| CN (1) | CN112292116A (en) |
| BR (1) | BR112020024737A2 (en) |
| CA (1) | CA3102693A1 (en) |
| MX (1) | MX2020013073A (en) |
| WO (1) | WO2019238968A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10774305B2 (en) | 2015-04-20 | 2020-09-15 | S-Biomedic Nv | Methods and compositions for changing the composition of the skin microbiome using complex mixtures of bacterial strains |
| ES2967029T3 (en) | 2016-10-19 | 2024-04-25 | S Biomedic Nv | Methods and compositions to change the composition of the skin microbiome using complex mixtures of bacterial strains |
| CN114901252A (en) * | 2019-10-03 | 2022-08-12 | S-生物医药有限公司 | Novel skin care compositions |
| EP3964211A1 (en) | 2020-09-07 | 2022-03-09 | DSM IP Assets B.V. | A composition comprising an ascorbyl phosphate, niacinamide and allantoin for treating acne |
| EP3970803A1 (en) | 2020-09-22 | 2022-03-23 | Beiersdorf AG | Cosmetic composition of low osmolality |
| CN117858693A (en) | 2021-08-24 | 2024-04-09 | 帝斯曼知识产权资产管理有限公司 | Novel use of at least one human milk oligosaccharide |
| WO2023135186A1 (en) * | 2022-01-12 | 2023-07-20 | S-Biomedic Nv | Skin care composition and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004014615A1 (en) * | 2004-03-23 | 2005-10-13 | Beiersdorf Ag | Taurine-containing preparations for improving the skin barrier |
| US20170065647A1 (en) * | 2014-05-07 | 2017-03-09 | The Regents Of The University Of California | Compositions and methods for treating skin and mucous membrane diseases |
| US10774305B2 (en) * | 2015-04-20 | 2020-09-15 | S-Biomedic Nv | Methods and compositions for changing the composition of the skin microbiome using complex mixtures of bacterial strains |
| KR20180123475A (en) * | 2016-02-05 | 2018-11-16 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | Compositions and methods for promoting skin health |
| ES2967029T3 (en) * | 2016-10-19 | 2024-04-25 | S Biomedic Nv | Methods and compositions to change the composition of the skin microbiome using complex mixtures of bacterial strains |
| DE102016012651A1 (en) | 2016-10-24 | 2018-04-26 | Beiersdorf Ag | Mehrkomponentenapplikator |
-
2019
- 2019-06-14 WO PCT/EP2019/065783 patent/WO2019238968A1/en active Application Filing
- 2019-06-14 MX MX2020013073A patent/MX2020013073A/en unknown
- 2019-06-14 CN CN201980038737.3A patent/CN112292116A/en active Pending
- 2019-06-14 KR KR1020217000961A patent/KR20210053874A/en not_active Application Discontinuation
- 2019-06-14 BR BR112020024737-5A patent/BR112020024737A2/en active Search and Examination
- 2019-06-14 US US17/251,301 patent/US20210251885A1/en active Pending
- 2019-06-14 EP EP19731948.6A patent/EP3806820A1/en active Pending
- 2019-06-14 CA CA3102693A patent/CA3102693A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020024737A2 (en) | 2021-03-23 |
| CA3102693A1 (en) | 2019-12-19 |
| CN112292116A (en) | 2021-01-29 |
| WO2019238968A1 (en) | 2019-12-19 |
| US20210251885A1 (en) | 2021-08-19 |
| EP3806820A1 (en) | 2021-04-21 |
| MX2020013073A (en) | 2021-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20210053874A (en) | Cosmetic preparations for acne | |
| KR101267198B1 (en) | A method which manufactures shampoo for preventing loss of hair and promoting growth of hair | |
| JPWO2004016236A1 (en) | Cosmetics | |
| JP2010132629A (en) | External composition for skin | |
| US9468597B1 (en) | Stabilized L-ascorbic acid skin serum | |
| CN109248105A (en) | A kind of makeup removing stick and preparation method thereof | |
| KR20210017590A (en) | Cosmetic composition comprising fermented vegetable oil and fermented vegetable extract | |
| CA3220643A1 (en) | Antimicrobial skincare composition and treatment | |
| EP2100593B1 (en) | Ternary mixtures with increased collagen synthesis | |
| CN103494737A (en) | Cosmetic preparation using ginger flower as anti-ageing and skin-protecting factor and preparation method of cosmetic preparation | |
| KR101418366B1 (en) | Composition containing bee venom and propolis for preventing or treating acne | |
| CN112472629A (en) | Alpinia officinarum and amomum tsao-ko sun-proof emulsion and preparation method thereof | |
| RU2657777C1 (en) | Cosmetic cream for care of sensitive skin of children with smoothing effect | |
| KR20110138709A (en) | Composition for improving acne comprising 5-aminolevulinic acid or ester thereof | |
| ES2961958T3 (en) | Skin care composition | |
| KR102215331B1 (en) | Laser treatment for pain relief How to make cosmetics For pain application | |
| KR20130103199A (en) | Composition for preventing sleeping drive | |
| KR100892742B1 (en) | Skin external composition for treating pimple | |
| BR122024004021A2 (en) | COSMETIC PREPARATION AGAINST ACNE | |
| KR101363028B1 (en) | A cosmetic composition for the prevention, improvement or treatment of acne vulgaris comprising the mixture of extract of Melissa officinalis, Citrus bergamia, leaves of Mentha arvensis, Eclipta prostrata and Hovenia dulcis Thunb | |
| RU2212229C1 (en) | Diurnal recovering cream | |
| JP6651104B1 (en) | Method for producing external composition | |
| KR101978716B1 (en) | Cosmetic composition for acne skin containing pha and plant extract | |
| JP6823938B2 (en) | Topical skin agent | |
| KR20240104964A (en) | A cosmetic composition containing a mixed extract as an active ingredient and having an effect of improving skin inflammation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal |